Catalio Capital Management, LP
In its 13F for Q2 2026 (holdings as of June 30, 2026, filed August 14, 2026), Catalio Capital Management, LP reported 39 stock positions worth $532.1 million. Its top holding was Avalyn Pharma (AVLN) at 10.4% of the portfolio, followed by Johnson & Johnson (JNJ, 6.6%) and Gilead Sciences (GILD, 6.4%). Compared with Q1 2026, it opened 10 new positions, sold out of 12, added to 15 and reduced 9. The biggest buy was a new position in Avalyn Pharma (AVLN) and the biggest sale Dianthus Therapeutics (DNTH, shares −94%).
- Most Recent 13F
- Q2 2026
- Location
- NEW YORK, NY
- CIK
- 0001958125
- Portfolio Value
- $532.1M (Q2 2026)
- SEC Filing
- 0001958125-26-000005 ↗ filed Aug 14, 2026
Holdings Value
Holdings 39 stocks · $532.1M
| AVLN Avalyn Pharma Inc. | 10.37% | 1,675,830 | $55.2M | New |
| JNJ Johnson & Johnson | 6.63% | 138,946 | $35.3M | New |
| GILD Gilead Sciences Inc. | 6.39% | 269,309 | $34.0M | Add +64.3% |
| BBIO Bridgebio Pharma Inc. | 6.37% | 455,041 | $33.9M | Add +5.3% |
| SNDX Syndax Pharmaceuticals Inc. | 4.99% | 1,215,698 | $26.6M | Add +16.5% |
| DFTX Definium Therapeutics Inc. | 4.97% | 562,672 | $26.5M | Reduce -45.8% |
| BMY Bristol-Myers Squibb Co. | 4.47% | 412,961 | $23.8M | Reduce -1.9% |
| PBLS Parabilis Medicines Inc. | 4.24% | 824,043 | $22.6M | New |
| NTRA Natera Inc. | 4.19% | 82,181 | $22.3M | Add +15.9% |
| INCY Incyte Corp. | 4.08% | 191,627 | $21.7M | Add +5.2% |
| SEPN Septerna Inc. | 3.37% | 536,152 | $18.0M | Add +82.1% |
| MLYS Mineralys Therapeutics Inc. | 3.29% | 648,722 | $17.5M | Add +47.8% |
| HTFL Heartflow Inc. | 3.21% | 583,055 | $17.1M | Add +44.5% |
| CRVS Corvus Pharmaceuticals Inc. | 3.03% | 1,080,888 | $16.1M | Add +21.2% |
| GPCR Structure Therapeutics Inc. | 2.79% | 276,550 | $14.8M | Add +8.3% |
| PTGX Protagonist Therapeutics Inc. | 2.46% | 106,799 | $13.1M | New |
| IRON Disc Medicine Inc. | 2.19% | 159,384 | $11.7M | Add +29.6% |
| EW Edwards Lifesciences Corp. | 2.12% | 124,778 | $11.3M | Reduce -13.7% |
| AXSM Axsome Therapeutics Inc. | 1.99% | 43,182 | $10.6M | New |
| RARE Ultragenyx Pharmaceutical Inc. | 1.98% | 316,252 | $10.6M | Reduce -62.8% |
| KLRA Kailera Therapeutics Inc. | 1.94% | 468,750 | $10.3M | New |
| KPTI Karyopharm Therapeutics Inc. | 1.73% | 940,855 | $9.2M | Add +4.8% |
| ODTX Odyssey Therapeutics Inc. | 1.61% | 457,839 | $8.6M | New |
| ASND Ascendis Pharma A/S | 1.59% | 31,759 | $8.5M | Reduce -75.4% |
| KARD Kardigan Inc. | 1.40% | 312,500 | $7.5M | New |
| ELDN Eledon Pharmaceuticals Inc. | 1.26% | 1,695,071 | $6.7M | Add +3.4% |
| FDMT 4D Molecular Therapeutics Inc. | 1.18% | 471,254 | $6.3M | New |
| MANE Veradermics Inc. | 1.06% | 45,856 | $5.6M | Reduce -73.6% |
| DYN Dyne Therapeutics Inc. | 1.02% | 244,929 | $5.4M | Reduce -13.4% |
| GUTS Fractyl Health Inc. | 0.92% | 6,168,749 | $4.9M | Add +12.3% |
| IMCR Immunocore Holdings PLC-ADR | 0.88% | 148,045 | $4.7M | Add +75.5% |
| DNTH Dianthus Therapeutics Inc. | 0.60% | 32,941 | $3.2M | Reduce -94.1% |
| BBOT Bridgebio Oncology Therapeut | 0.46% | 318,407 | $2.4M | New |
| TARA Protara Therapeutic Inc. | 0.37% | 520,148 | $2.0M | Reduce -10.3% |
| HYPR Hyperfine Inc. | 0.33% | 1,320,041 | $1.8M | No change |
| ATAI Ataibeckley Inc. | 0.20% | 196,858 | $1.0M | No change |
| MGX Metagenomi Therapeutics Inc. | 0.12% | 528,993 | $630K | No change |
| OM Outset Medical Inc. | 0.10% | 118,279 | $511K | No change |
| FTH Faeth Therapeutics Inc. | 0.07% | 14,718 | $368K | No change |
Portfolio Sells Q1 2026 → Q2 2026
| DNTH Dianthus Therapeutics Inc. | Reduce -94.1% | 0.60% | −9.22 |
| ASND Ascendis Pharma A/S | Reduce -75.4% | 1.59% | −4.58 |
| TERN Terns Pharmaceuticals Inc. | Sold out | 0.00% | −4.50 |
| SLNO Soleno Therapeutics Inc. | Sold out | 0.00% | −4.04 |
| BSX Boston Scientific Corp. | Sold out | 0.00% | −3.92 |
| CYTK Cytokinetics Inc. | Sold out | 0.00% | −2.97 |
| ADPT Adaptive Biotechnologies | Sold out | 0.00% | −2.10 |
| KALV Kalvista Pharmaceuticals Inc. | Sold out | 0.00% | −1.79 |
| RARE Ultragenyx Pharmaceutical Inc. | Reduce -62.8% | 1.98% | −1.74 |
| QURE Uniqure NV | Sold out | 0.00% | −1.68 |
| MANE Veradermics Inc. | Reduce -73.6% | 1.06% | −1.23 |
| ABVX Abivax SA-ADR | Sold out | 0.00% | −1.10 |
| BMY Bristol-Myers Squibb Co. | Reduce -1.9% | 4.47% | −0.86 |
| SUPN Supernus Pharmaceuticals Inc. | Sold out | 0.00% | −0.67 |
| PHAT Phathom Pharmaceuticals Inc. | Sold out | 0.00% | −0.57 |
| NAMS Newamsterdam Pharma Co. NV | Sold out | 0.00% | −0.56 |
| TYRA Tyra Biosciences Inc. | Sold out | 0.00% | −0.54 |
| EW Edwards Lifesciences Corp. | Reduce -13.7% | 2.12% | −0.30 |
| TARA Protara Therapeutic Inc. | Reduce -10.3% | 0.37% | −0.26 |
| DYN Dyne Therapeutics Inc. | Reduce -13.4% | 1.02% | −0.05 |
| DFTX Definium Therapeutics Inc. | Reduce -45.8% | 4.97% | +0.88 |
Portfolio Buys Q1 2026 → Q2 2026
| AVLN Avalyn Pharma Inc. | New | 10.37% | +10.37 |
| JNJ Johnson & Johnson | New | 6.63% | +6.63 |
| PBLS Parabilis Medicines Inc. | New | 4.24% | +4.24 |
| PTGX Protagonist Therapeutics Inc. | New | 2.46% | +2.46 |
| AXSM Axsome Therapeutics Inc. | New | 1.99% | +1.99 |
| KLRA Kailera Therapeutics Inc. | New | 1.94% | +1.94 |
| SEPN Septerna Inc. | Add +82.1% | 3.37% | +1.90 |
| GILD Gilead Sciences Inc. | Add +64.3% | 6.39% | +1.62 |
| ODTX Odyssey Therapeutics Inc. | New | 1.61% | +1.61 |
| KARD Kardigan Inc. | New | 1.40% | +1.40 |
| NTRA Natera Inc. | Add +15.9% | 4.19% | +1.23 |
| FDMT 4D Molecular Therapeutics Inc. | New | 1.18% | +1.18 |
| HTFL Heartflow Inc. | Add +44.5% | 3.21% | +1.16 |
| MLYS Mineralys Therapeutics Inc. | Add +47.8% | 3.29% | +0.80 |
| KPTI Karyopharm Therapeutics Inc. | Add +4.8% | 1.73% | +0.68 |
| IRON Disc Medicine Inc. | Add +29.6% | 2.19% | +0.55 |
| INCY Incyte Corp. | Add +5.2% | 4.08% | +0.50 |
| BBOT Bridgebio Oncology Therapeut | New | 0.46% | +0.46 |
| GUTS Fractyl Health Inc. | Add +12.3% | 0.92% | +0.40 |
| IMCR Immunocore Holdings PLC-ADR | Add +75.5% | 0.88% | +0.35 |
| CRVS Corvus Pharmaceuticals Inc. | Add +21.2% | 3.03% | +0.31 |
| GPCR Structure Therapeutics Inc. | Add +8.3% | 2.79% | +0.22 |
| ELDN Eledon Pharmaceuticals Inc. | Add +3.4% | 1.26% | +0.20 |
| SNDX Syndax Pharmaceuticals Inc. | Add +16.5% | 4.99% | −0.10 |
| BBIO Bridgebio Pharma Inc. | Add +5.3% | 6.37% | −0.33 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 39 | $532.1M | AVLN, JNJ, GILD, BBIO, SNDX |
| Q1 2026 | 41 | $478.7M | DNTH, BBIO, ASND, BMY, SNDX |
| Q4 2025Amended | 45 | $565.8M | GILD, BMY, BSX, BBIO, LLY |
| Q3 2025 | 38 | $540.9M | LLY, ABBV, BBIO, ISRG, ASND |
| Q2 2025 | 40 | $476.9M | LLY, BBIO, SLNO, ASND, ISRG |
| Q1 2025 | 35 | $403.4M | BDX, SWTX, BBIO, EW, ASND |
| Q4 2024 | 33 | $457.1M | BDX, ASND, BMY, SWTX, BPMC |